Clinical Trial Update: Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. [Phase 4]

View source ↗

Summary

This clinical trial update states that a Phase 4 open-label study of zoledronic acid in patients with bone lesions due to multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Zometa (Zoledronic acid)

Snippet

Sponsor: Novartis | Conditions: Multiple Myeloma | Phase 4 | Status: WITHDRAWN